Zang Xiaoyi, Du Wenjuan, Geng Funeng, Meng Panpan, E Lingling, Zhang Haizhong, Wang Xinling, Li Lin, Xiao Rui
Department of Stomatology, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
Graduate School, Chinese PLA General Hospital, Beijing, China.
Ann Transl Med. 2022 Jun;10(12):721. doi: 10.21037/atm-22-2734.
Allergic contact stomatitis (ACS) is common among people with allergic constitution and who have allergy reaction to specific allergen such as drugs, food, and materials because of immune dysfunction. With the development of materials science, the increasing diversity of cosmetics and food additives has gradually raised the incidence rate of ACS. Now systemic and local therapy are adopted in the therapy of ACS. However, the systemic therapy would drop the drugs' concentration after it reaches the treatment area through the layers of human barriers, while the locally-used drugs such as collutory may not be suitable for patients with skin lesion. Kangfuxin contains a variety of biological extracts which is anti-inflammatory and curative and can produce connective tissues whether it's skin or mucous membrane. It can be used not only in non-oral diseases such as gastric ulcer or gynecological diseases, but also in the treatment of recurrent aphthous ulcer and many kinds of stomatitis and has shown good anti-inflammatory and curative effects. This study aimed to explore the effectiveness of Kangfuxin solution as a local-used adjuvant drug to treat ACS.
We present a 22-year-old male with ACS whose complaint at the first visit was severe pain, accompanied by salivation, tongue enlargement, bleeding, tonsil enlargement, and symptoms of difficulty in eating, fatigue, and dizziness. After the physical and laboratory examination, we found no abnormalities other than a history of eating the kiwi fruit, which is a common allergen. Thus, he was diagnosed as ACS. In this case, we provided a pharmacologic therapeutic intervention of chlorpheniramine (one tablet, three times a day) and Kangfuxin solution (gargle for 15 min, three times a day) with advice that no exposure to the allergen. On the third day, the patient felt no significant relief of symptoms, while one week after the first visit, the symptoms had obviously alleviated and most of the red lip erosion disappeared. The patient recovered completely with no discomfort in ten days after the initial visit.
This study investigated the therapeutic effect of Kangfuxin solution combined with chlorpheniramine on ACS.
过敏性接触性口炎（ACS）在过敏体质人群中较为常见，这类人群由于免疫功能失调，会对特定过敏原如药物、食物和材料产生过敏反应。随着材料科学的发展，化妆品和食品添加剂的种类日益增多，逐渐提高了ACS的发病率。目前，ACS的治疗采用全身治疗和局部治疗。然而，全身治疗的药物在通过人体多层屏障到达治疗部位后，药物浓度会下降，而局部使用的药物如含漱剂可能不适用于有皮肤损伤的患者。康复新含有多种生物提取物，具有抗炎和治愈作用，无论是皮肤还是黏膜，都能促使结缔组织生成。它不仅可用于治疗胃溃疡或妇科疾病等非口腔疾病，还可用于治疗复发性阿弗他溃疡和多种口腔炎，并已显示出良好的抗炎和治愈效果。本研究旨在探讨康复新液作为局部辅助用药治疗ACS的有效性。
我们报告一例22岁患有ACS的男性患者，其首次就诊时的主诉为剧痛，伴有流涎、舌头肿大、出血、扁桃体肿大以及进食困难、疲劳和头晕等症状。经过体格检查和实验室检查，除了有食用猕猴桃（一种常见过敏原）的病史外，未发现其他异常。因此，他被诊断为ACS。在该病例中，我们给予了氯苯那敏（一片，每日三次）和康复新液（含漱15分钟，每日三次）的药物治疗干预，并建议避免接触过敏原。第三天，患者症状无明显缓解，而在首次就诊一周后，症状明显减轻，大部分唇部糜烂消失。初次就诊十天后，患者完全康复，无任何不适。
本研究探讨了康复新液联合氯苯那敏治疗ACS的疗效。
